Fluorobenzenes - Pharmacology
Research News and Information

Sunday, November 22, 2009

Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins?

30 Jul 2009 OBJECTIVES: Low levels of 25-hydroxyvitamin D are associated with higher risk of cardiovascular morbidity and mortality. Large trials demonstrated that statins significantly decrease cardiovascular morbidity and mortality. 7-dehydrocholesterol is ... Read more...

Interactions of serotonin (5-HT)2 receptor-targeting ligands and nicotine: locomotor activity studies in rats.

30 Jul 2009 Male Wistar rats were used to verify the hypothesis that serotonin (5-HT)(2A) or 5-HT(2C) receptors may control the locomotor effects evoked by nicotine (0.4 mg/kg). The 5-HT(2A) receptor antagonist (M100,907), the 5-HT(2A) receptor agonist (DOI), ... Read more...

Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat.

22 Jul 2009 We have recently reported that transgenic (mRen2)27 rats (Ren2 rats) exhibit pulmonary arterial hypertension (PAH), which is, in part, mediated by oxidative stress. Since 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) exhibit ... Read more...

Latest indexed articles for 'Fluorobenzenes - Pharmacology'

These are the very latest articles for this heading:

• Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? 30 Jul 2009
• Interactions of serotonin (5-HT)2 receptor-targeting ligands and nicotine: locomotor activity studies in rats. 30 Jul 2009
• Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. 22 Jul 2009
• Statins and angiogenesis: is it about connections? 14 Jul 2009
• Derivation of a retinoid X receptor scaffold from peroxisome proliferator-activated receptor gamma ligand 1-Di(1H-indol-3-yl)methyl-4-trifluoromethylbenzene. 29 Jun 2009
• Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy. 27 Jun 2009
• Role of dopamine transporters in the behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in nonhuman primates. 5 May 2009
• Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. 29 Apr 2009
• Blockade of the serotonin 5-HT2A receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self-administration model. 30 Mar 2009
• Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. 26 Mar 2009
• Reversal of voltage-dependent erectile responses in the Zucker obese-diabetic rat by rosuvastatin-altered RhoA/Rho-kinase signaling. 27 Feb 2009
• JUPITER strikes earth. 27 Feb 2009
• Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion. 27 Feb 2009
• The role of C-reactive protein (CRP) and statin treatment in reducing cardiovascular risk. 27 Feb 2009
• Rosuvastatin positively changes nerve electrophysiology in diabetic rats. 27 Feb 2009
• Tricyclic HIV integrase inhibitors V. SAR studies on the benzyl moiety. 25 Feb 2009
• Rosuvastatin given during reperfusion decreases infarct size and inhibits matrix metalloproteinase-2 activity in normocholesterolemic and hypercholesterolemic rabbits. 30 Jan 2009
• Inhibition of monoamine oxidases desensitizes 5-HT1A autoreceptors and allows nicotine to induce a neurochemical and behavioral sensitization. 26 Jan 2009
• Blockade of 5-HT2A receptors suppresses hyperthermic but not cardiovascular responses to psychosocial stress in rats. 25 Jan 2009
• Genetic deletion of MAO-A promotes serotonin-dependent ventricular hypertrophy by pressure overload. 5 Jan 2009

See a longer list of these articles.

Technical information about 'Fluorobenzenes'

Registry Number: 0

Descriptor UI: D005464

Alternative terms: Fluorobenzenes;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D02.455.526.510.432;

History Note: 74